Novel Drug Targets and RNA Epigenetics in Cancer Therapy
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Structure and Dynamics".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 15
Special Issue Editor
Special Issue Information
Dear Colleagues,
RNA epigenetics, encompassing modifications such as methylation, acetylation, and pseudouridylation of RNA molecules, has emerged as a crucial layer of gene expression regulation. These modifications influence RNA stability, localization, translation, and splicing, significantly impacting cellular processes. Aberrations in RNA epigenetics have been increasingly linked to cancer progression and drug resistance, making them promising targets for novel therapeutic strategies.
In this Special Issue, we aim to highlight the recent advancements in understanding RNA epigenetics and its role in cancer biology. We encourage submissions that explore novel drug targets related to RNA modifications, such as RNA methyltransferases, demethylases, and RNA-binding proteins, as well as the development of small-molecule inhibitors or RNA-targeted therapies. Additionally, we welcome contributions that utilize cutting-edge technologies, including RNA-seq, CRISPR screening, and single-cell analysis, to investigate the dynamics of RNA modifications in tumorigenesis and therapeutic response.
By focusing on these novel drug targets and the role of RNA epigenetics in cancer growth, progression, and therapy resistance, this Special Issue seeks to provide insights into innovative approaches for precision oncology. We invite researchers to contribute original research articles, reviews, and short communications to advance the field of RNA epigenetics in cancer treatment.
Prof. Dr. Manjeet K. Rao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RNA modifications
- cancer epigenetics
- novel drug targets
- RNA therapeutics
- tumorigenesis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
